La réponse du système immunitaire.

Mise à jour, l'article date de mai 2015


Dendritic cell vaccines: These vaccines have shown the most success so far in treating cancer. Sipuleucel-T (Provenge), which is approved for the treatment of advanced prostate cancer, is an example of a dendritic cell vaccine.

Dendritic cells are special immune cells in the body that help the immune system recognize cancer cells. They break down cancer cells into smaller pieces (including antigens), and then hold out these antigens so other immune cells called T cells can see them. The T cells then start an immune reaction against any cells in the body that contain these antigens.

Dendritic cell vaccines are made from the person in whom they will be used. The process used to create this type of vaccine (known as an autologous vaccine) is complex and expensive. Doctors remove some immune cells from the patient’s blood and expose them in the lab to cancer cells or cancer antigens, as well as to other chemicals that turn the immune cells into dendritic cells and help them grow. The dendritic cells are then injected back into the patient, where they should cause an immune response to cancer cells in the body.

---

Les vaccins de cellules dendritiques: Ces vaccins ont montré le plus de succès à ce jour dans le traitement du cancer. Le Sipuleucel-t (Provenge), qui est approuvé pour le traitement du cancer de la avancé, est un exemple d'un vaccin de cellules dendritiques.

Les cellules dendritiques sont des cellules immunitaires spécifiques dans le corps qui aident le système immunitaire à reconnaître les cellules cancéreuses. Ils décomposent les cellules cancéreuses en petits morceaux (y compris les antigènes), puis maintiennent ces antigènes afin que d'autres cellules immunitaires appelées lymphocytes T puissent les voir. Les cellules T de départ ont alors une réaction immunitaire contre les cellules de l'organisme qui contiennent ces antigènes.

Les vaccins à cellules dendritiques sont fabriqués à partir de la personne à laquelle ils seront utilisés. Le processus utilisé pour créer ce type de vaccin (connu comme un vaccin autologue) est complexe et coûteux. Les médecins extraient certaines cellules immunitaires du sang du patient et les exposent dans le laboratoire aux cellules cancéreuses ou aux antigènes du cancer, ainsi qu'à d'autres produits chimiques qui transforment les cellules immunitaires en cellules dendritiques et les aident à grandir. Les cellules dendritiques sont ensuite injectées dans le patient, où elles devraient provoquer une réponse immunitaire contre les cellules cancéreuses dans le corps.

(Jan. 14, 2008) — In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors. The molecule comes from a protein found in all cells of the body; however, immune cells appear to respond to it only when it is present on the surface of cells within a tumor.

En expérimentant avec des souris, les chercheurs ont trouvé que le système immunitaire peut utiliser, de façon surprenante, une molécule très commune pour reconnaitre les tumeurs de la prostate. La molécule vient d'une protéine trouvée dans toutes les cellules du corps. Toutefois, les cellules du système immunitaire semble répondre seulement quand elle est présente à la surface des cellules de la tumeur.


Understanding how this protein, known as histone H4, signals the immune system to respond to malignant cells may help researchers refine immunotherapy strategies that harness the body's own immune system to fight tumors. Some types of immunotherapy are already being tested in patients, but many questions remain unanswered. In particular, researchers want to know if tumor cells display molecular signposts that tell the immune system, "I'm a cancer cell, destroy me."

Comprendre comment cette molécuel connue sous le nom d'histone H4 appelle le système immunitaire pour répondre aux cellules cancéreuses pour combattre la tumeur pourrait aider les chercheurs à rafiner leurs stratégies avec le système immunitaire. quelques types d'immunothérapie sont déja en cours d'être tester mais plusieurs questions demeurent. en particulier, les chercheurs veulent savoir si les cellules cancéreuses affichent ces molécule spour dire au système immunitaire " je suis une cellule cancéreuse, détruisez-moi".[/b)

Howard Hughes Medical Institute investigator James P. Allison and his team report finding one such signpost in prostate tumors in mice. The finding points toward possible improvements in immunotherapy.

Les chercheurs affirment avoir trouvé un de ces messages chez les celules cancéreuses des souris. Ce qui pourrait amener des développements dans les immunothérapies.

"We know very little about how the immune system responds to tumors, especially early tumors," said Allison, director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center in New York. "Is the tumor at that stage invisible, or can immune cells detect it? And if they can detect it, can they mount a response? Those are the two big questions."

"nous en savons très peu sur comment le système immunitaire répond aux tumeurs, spécialement les très petites tumeurs, Est-ce que la tumeur à ce stage est invisible ou si les cellules du système immunitaire peuvent la détecter. Et si elles peuvent la détecter, peuvent-elles faire une réponse. Ce sont là deux grosses questions."

Allison's research, published in the January 11, 2008, issue of Science, found that immune cells can, in fact, detect prostate cancer, at least in lab mice. However, the immune system mounts only a feeble attack against the tumor.

Les checheurs croient que la tumeur peut être détecter mais que le système immunitaire ne peut que faire une très faible réponse.

But the signpost Allison's team identified might make revving up that feeble response much easier.

Mais ce que l'équipe de chercheurs de Allison a trouvé pourrait aider à augmenter cette réponse.

The strategy relies on a specific type of immune system cell called a killer T cell. Each of these cells bristles with thousands of receptors that recognize molecules that do not belong in the body. When a T cell recognizes a foreign molecule, it tries to destroy the cell carrying it. The T cell then replicates, making copies that also latch onto the same foreign molecule.

In 1982, while at the University of Texas at Austin, Allison discovered T cell antigen receptors, the fork-like proteins that recognize the molecular signals on invading cells. Each T cell has a different receptor as determined by genetics and a random process. There are trillions of different T cell receptors possible, a number greater than the number of cells in the human body.

In normal tissue, the distribution of receptors found on T cells is random. That is, a batch of T cells will have a range of receptors, with none being more common than the others.

But in the new work, one of Allison's colleagues, Peter Savage, discovered that the cancerous prostate glands of mice harbored many T cells carrying a specific receptor. That meant that a single T cell had recognized the malignancy and had replicated.

Savage found the overrepresented receptor in 15 of 20 mice with prostate cancer. "That told us something was going on," said Allison. "You don't see this in normal mice."

At this point, the team knew that the immune system of the mice was recognizing a particular signpost of malignancy. But they had no idea what the signpost was.

"The obvious question was, 'What are these T cells seeing?'" said Allison. "And that's when the hard work started."

The team chopped up tumor cells in a dish and mixed them with antigen presenting cells and T cells carrying the receptor they had identified. The T cells switched on, which "showed we had really gotten the right receptor," said Allison. However, during control experiments, the team also found that nearly any type of tissue, if it was chopped up, would activate the T cells.

"This started some head scratching," said Allison. Because if every tissue activated the T cells, it meant that the signpost was not specific to the cancer cells.

The mystery deepened when mice were engineered to produce T cells that carried only the receptor of interest. Those cells did not attack every tissue. They only attacked -- albeit feebly -- the prostate tumors. It was a conundrum.

Returning to their experiments in the lab dish, the team decided to focus on specific parts of the tumor cells. They soon discovered that only molecules from the nucleus activated their T cells.

"This was really a surprise, because normally, nuclear proteins don't get fed onto the cell surface," said Allison. And in living animals, T cells only recognize molecules on the surface of other cells -- they can't peer deep into the nucleus.

The team then searched for particular nuclear proteins that activated the T cells. They eventually struck on histone H4. As the wrapper that sheaths the DNA inside all cells, histones are abundant in the nucleus. The finding explained why the normal cells, when chopped up, had activated the T cells -- their histones were being exposed.

The team had identified the molecular signpost that activated the T cells, but they had also landed on another big question -- how do the histones rise to the surface of the tumor cells. "Every cell has a ton of histone, and we just don't know why the tumor cells put it on their surface," said Allison.

The team is now examining the blood of patients with prostate and other cancers to see if people, like mice, carry T cells sensitive to histone. If so, "then we can take those cells out and try to activate them," said Allison. "Those cells already recognize the tumor. If we can mobilize them, maybe it will have a therapeutic effect."

Allison and his colleagues are also conducting studies to determine whether the presence of histone H4-reactive T cells in the blood could be used as a diagnostic marker for the early detection of prostate cancer.